Introduction {#sec1}
============

Total knee arthroplasty (TKA), one of the most common curative operations for end-stage arthritis of the knee, can effectively relieve pain, improve the knee function, and improve the quality of patients' life \[[@cit0001]--[@cit0003]\]. In the United States, there are over 600,000 TKAs and over 285,000 total hip arthroplasties (THAs) performed every year \[[@cit0004]\]. The demand for primary TKA is predicted to grow by 673%, to reach 3.48 million by 2030 in the United States. Although the operation has good outcomes and is generally well tolerated, the complications of blood transfusion are also severe, including infection, transfusion-related liver damage, hemolysis, immune suppression, prolonged rehabilitation duration and allergic reactions \[[@cit0005]\], and blood loss is a major concern both during and after TKA surgery \[[@cit0006]\].

In western countries, venous thromboembolism (VTE) is composed of pulmonary embolism (PE) and deep venous thrombosis (DVT), and it has been identified as a significant public health concern \[[@cit0007], [@cit0008]\]. Undergoing THA and TKA could significantly increase the risk of VTE, whose prevalence rate was estimated as 60% without appropriate prophylaxis \[[@cit0009]\]. Venous thromboembolism is also a major contributor to morbidity and mortality among orthopedic patients and body mass index (BMI) could be correlated with it \[[@cit0008]\]. Mortality rates from VTE following lower limb arthroplasty are low. It was estimated that before 1980, the VTE prevalence rate without prophylaxis was about 15--30%, but it has been reduced to 1--2% after the contemporary prophylactic strategies were applied in 2001 \[[@cit0010]\]. Now, even though the administered drug remained controversial, the western guidelines have strongly recommended routine chemoprophylaxis to reduce the incidence of VTE for patients who underwent TKA \[[@cit0011]\].

Tranexamic acid (TXA) is an analog of lysine that can reduce blood transfusion and loss, and it can efficiently inhibit fibrinolysis through hindering plasmin's binding to fibrin and activation of plasminogen \[[@cit0002], [@cit0012], [@cit0013]\]. Tranexamic acid has been applied widely in cardiac surgery, tonsillectomy, spinal surgery, hemophilia, gynecological surgery and oral surgery \[[@cit0014]\]. It has also been shown that TXA can significantly reduce blood loss and transfusion rates after TKA without increasing the incidence of VTE \[[@cit0015]\]. As reported by recent meta-analyses, the effect of intravenous (IV) TXA on blood loss was estimated to be up to around 600 ml for TKA \[[@cit0016]--[@cit0018]\]. Tranexamic acid (TXA) elicits an anti-fibrinolytic effect; in theory, TXA can be used to reduce blood loss in TKA. European and U.S. studies on this topic have shown that the intravenous administration of TXA can significantly reduce post-operative blood loss and the need for transfusion. However, limited information has been presented regarding the effectiveness and safety of TXA for Chinese patients subjected to TKA \[[@cit0019]\].

Although IV TXA has been well proved to be safe for healthy people, it was still unclear if this held true for patients with a history of VTE. It has been discredited that TXA acts as a procoagulant, and it had antithrombotic effects \[[@cit0020]\]. However, whether TXA had positive effects on VTE after TKA was still not well-defined, which was restricted by the small sample size. Thus, our study was designed to explore the effects of using TXA after first TKA surgery on the incidence rates of VTE, and analyze risk factors that affect the incidence of symptomatic VTE.

Material and methods {#sec2}
====================

Patients' characteristics {#sec2.1}
-------------------------

Prior to this trial, approval from the Institutional Ethics Committee of Peking Union Medical College Hospital was obtained. Additionally, written informed consent and research authorizations were obtained prospectively prior to surgery. From January 2013 to May 2015, multiple TKA cases involving 1880 patients were included in this study and randomized to the experimental group and control group. Inclusion criteria: (i) all the patients were undergoing primary TKA; (ii) the patients were over 18 years old; (iii) patients who received TXA injection were in the perioperative period; (iv) patients underwent a standardized VTE prophylactic anticoagulant therapy postoperatively; (v) all patients included had given written consent. Exclusion criteria: (i) patients had a history of venous thromboembolism, pulmonary embolism and coronary heart disease; (ii) patients had coagulopathy; (iii) oral non-steroidal anti-inflammatory drugs (NSAIDs) were discontinued for less than 1 week; (iv) patients were clearly allergic to TXA; (v) patients had severe liver and kidney dysfunctions; (vi) patients had high risk of thrombosis. In the end, a total of 720 cases (878 knees) were included in the TXA group, including 562 unilateral TKA cases and 158 bilateral TKA cases. Among them, there were 658 cases with primary osteoarthritis and 53 cases with rheumatoid arthritis.

Operation {#sec2.2}
---------

Procedures were completed by four senior orthopedic surgeons for objectivity and reliability of experiments in this randomized comparison study (RCT). Patients randomized to the experimental group used TXA injection while those in the control group received placebo injection. The surgical techniques and procedures applied were up to date. Prophylactic intravenous antibiotics were given to all patients 30 min before the surgery. During the operation, medial parapatellar arthrotomy as the standard approach of exposure of the knee joint allowed adequate exposure for TKA. Then, anterior midline incision, the most commonly used skin incision for primary TKA, and a utilitarian extensile approach to the knee were done with the knee in flexion to allow the subcutaneous tissue to fall medially and laterally, improving exposure and obviating the need for raising skin flaps \[[@cit0021]\]. After the surgery, all patients used the posterior stabilized prosthesis and were fixed with bone cement. The tourniquet was not released until skin closure. A 16 gauge drainage tube was placed, and was opened after 3 to 4 h of postoperative clamping. Residual volume of the tube was less than 200 ml within 24 h, so the catheter/tube was then removed \[[@cit0022]\].

Evaluation and diagnosis of venous thromboembolism {#sec2.3}
--------------------------------------------------

Deep vein thrombosis was assessed before performing TKA. Patients were assessed with the Wells score to determine whether there was obvious swelling of the lower limbs (greater than the preoperative value of 3 cm), pain or Homan positiveness and usage of Doppler ultrasonography for investigating DVT. Variate scores indicate different probability of DVT diagnosis. A score \< 2.0 means low probability, 2.0--6.0 means mediate probability, while \> 6.0 indicates high probability. Diagnostic criteria: (i) venous lumen could not be closed; (ii) the cavity was hypoechoic or echoless; (iii) there was no or only a small amount of blood flow signal within venous thrombosis; (iv) the pulse of Doppler showed no blood flow or the spectrum did not change with respiration. If chest pain and chest tightness occur, patients should be immediately tested for pulmonary embolism with a CT pulmonary angiogram (CTPA).

Basic precautions {#sec2.4}
-----------------

The process of TKA should be gentle and delicate to avoid intravenous intimal injury. The limb was raised to prevent deep venous reflux disorder or blood would not successfully flow around the body. Patients were encouraged to stand up, to perform early functional exercise, to get out of bed, to take deep breaths and to cough. The patients were suggested to drink more water, so that dehydration could be avoided.

Physical and drug prophylactic anticoagulation {#sec2.5}
----------------------------------------------

An intermittent pneumatic foot vein pump and stretch socks were used. The patients were subcutaneously given enoxaparin sodium (Clexane, Sanofi Aventis) or orally given rivaroxaban (Xarelto, Bayer). In the first stage, enoxaparin sodium was given once a day, and the dosage was adjusted according to the patients' weight. Some of the patients were subcutaneously given conventional doses (i.e. low-molecular-weight heparin) 12--24 h after TKA surgery (2--4 h after epidural catheter removal), and some were given half of the conventional doses 4--6 h after surgery, and the next day conventional doses were given. This process was generally repeated once every 24 h for 3--5 days. In the second stage, subcutaneous injection of low molecular weight heparin or oral administration of warfarin 10 mg once a day was used for 10--14 days after surgery.

Methods of using tranexamic acid {#sec2.6}
--------------------------------

The use of TXA was mainly divided into two types: (i) 15 mg/kg TXA was intravenously injected in 15 min before release of the tourniquet; (ii) 15 mg/kg TXA with 1 g/50 ml TXA topical application was intravenously injected before tourniquet release.

Risk factors of symptomatic venous thromboembolism {#sec2.7}
--------------------------------------------------

The risk factors were selected based on the following: (i) relevant factors in the literature report; (ii) experience and accumulation in clinical work; (iii) factors that may be relevant but pending confirmation; (iv) indicators that were relatively independent, or may have certain relevance, but without a direct causal relationship. Thus, patients' related factors were applied, including gender, age, BMI, diagnosis, personal history (i.e. history of smoking and alcohol consumption), comorbidities (i.e. hypertension, diabetes, cerebrovascular disease, malignancy history, arrhythmia) and American Anesthesiologists Association (ASA) score; patients classified as III and above are considered not qualified for an anesthesia. Preoperative laboratory tests were reviewed, including hematocrit (Hct), hemoglobin (Hgb), platelet count (Plt), prothrombin time (PT), international normalized ratio (INR), activated partial thrombin time (APTT), fibrinogen (Fbg) and D-dimer. Preoperative medication history was recorded, including aspirin and lipid-lowering agents. Operation-related factors were also described, including the surgeons (i.e. A, B, C, D), anesthesia, surgery (i.e. unilateral TKA and one-stage bilateral TKA), usage of tourniquet, and placement of drainage after operation.

Statistical analysis {#sec2.8}
--------------------

All indicators were analyzed with SPSS 21.0 software (IBM, USA). Count data were presented as percentages, and measurement data were presented as mean and standard deviation. The risk factors for symptomatic VTE were analyzed by single factor analysis (i.e. χ^2^ test and independent sample *t*-test) and the multivariate logistic regression test. *P* \< 0.05 was considered to indicate statistical significance.

Results {#sec3}
=======

Basic information of included patients {#sec3.1}
--------------------------------------

A total of 1880 TKA patients were recruited; 720 of them received TXA injection while 1160 received placebo sodium chloride injection. There were significant differences in symptomatic VTE, indicating the effectiveness of TKA ([Table I](#t0001){ref-type="table"}). No close association between thigh perimeter and TXA was found (*p* \> 0.05, [Figure 1](#f0001){ref-type="fig"}). Tranexamic acid was found to be associated with adverse effects ([Table II](#t0002){ref-type="table"}), which would possibly reduce the blood transfusion and blood loss. A total of 24 patients were found with symptomatic VTE, including 16 (2.2%) patients of symptomatic DVT and 8 (1.11%) cases of symptomatic PE. No deaths occurred 30 days after operation.

![Comparison between tranexamic acid group and control group regarding thigh perimeter](AMS-16-3-39645-g001){#f0001}

###### 

Baseline characteristics of subjects treated with traditional schemes and tranexamic acid

  Indicators                  Controls       Tranexamic acid   χ^2^/*t*   *P*-value
  --------------------------- -------------- ----------------- ---------- --------------
  Number                      1160           720                          
  Age, mean ± SD \[years\]    68.4 ±8.93     66.47 ±7.64       0.168      0.868
  Gender, *n* (%):                                                        
   Male                       184 (15.86)    176 (24.44)       21.360     \< 0.001^\*^
   Female                     976 (84.14)    544 (75.56)                  
  BMI \[kg/m^2^\]:            26.92 ±3.84    26.74 ±4.08       −0.431     0.852
   BMI \< 25                  431 (37.16)    253 (35.14)       0.780      0.502
   BMI ≥ 25                   729 (62.84)    467 (64.86)                  
  Protopathy, *n* (%):                                                    
   Osteoarthritis                            658 (91.39)                  
   Rheumatoid arthritis                      53 (7.36)                    
   Others                                    9 (1.25)                     
  Diagnosis, *n* (%):                                                     
   OA                         1067 (91.98)   658 (91.39)       0.207      0.667
   Non-OA                     93 (8.02)      62 (8.61)                    
  Surgery, *n* (%):                                                       
   Unilateral TKA             817 (70.43)    562 (78.06)       13.312     \< 0.001^\*^
   Bilateral TKA              343 (29.57)    158 (21.94)                  
  Symptomatic VTE, *n* (%):                                               
   Yes                        39 (3.36)      24 (3.33)         0.001      1.000
   No                         1121 (96.94)   696 (96.67)                  
  PE, *n* (%):                                                            
   Yes                        2 (0.17)       6 (0.83)          3.150      0.170
   No                         1158 (99.83)   714 (99.17)                  
  Near-end DVT, *n* (%):                                                  
   Yes                        6 (0.51)       6 (0.83)          0.290      0.821
   No                         1154 (99.49)   714 (99.17)                  

BMI -- body mass index, OA -- osteoarthritis, TKA -- total knee arthroplasty, VTE -- venous thromboembolism, PE -- pulmonary embolism, DVT -- deep vein thrombosis.

###### 

Indicators related to peri-operative blood of subjects treated with traditional schemes and tranexamic acid

  Indicators                                            Controls     Tranexamic acid   χ^2^/*t*   *P*-value
  ----------------------------------------------------- ------------ ----------------- ---------- -----------
  Number                                                1160         720                          
  Peri-operative blood transfusion, *n*:                                                          
   Unilateral                                           312/817      253/562           2.666      0.103
   Bilateral                                            343/343      158/158           0          1
   Total                                                655          411               0.019      0.89
  Total peri-operative blood loss, mean ± SD \[ml\]:                                              
   Unilateral                                           1064 ±78.7   992 ±68.2         20.27      \< 0.001
   Bilateral                                            1682 ±63.5   1564 ±93.6        32.54      \< 0.001
  Peri-operative hidden blood loss, mean ± SD \[ml\]:                                             
   Unilateral                                           523 ±78.4    505 ±62.8         5.21       \< 0.001
   Bilateral                                            765 ±86.0    862 ±75.6         24.88      \< 0.001

Analysis of risk factors in patients with symptomatic venous thromboembolism {#sec3.2}
----------------------------------------------------------------------------

Among 720 patients who received TXA, 24 had symptomatic VTE and 696 had other symptoms. [Tables III](#t0003){ref-type="table"}--[VI](#t0006){ref-type="table"} show the results of univariate analysis of perioperative TKA. The results show that BMI, Fbg, and surgical approach (i.e. unilateral TKA/a bilateral TKA) were significantly associated with symptomatic VTE (*p* \< 0.05). On the other hand, diagnosis, personal history of smoking and alcohol, comorbidities (i.e. hypertension, diabetes, cerebrovascular disease, arrhythmia and hyperlipidemia), the number of complications, ASA score, preoperative test (i.e. hemoglobin, platelet, D-dimer, INR, PT, APTT), surgeons, anesthesia, drainage tube clamped or not, and the use of hemostatic zone showed no significant difference. Then, BMI (OR = 0.213, 95% CI: 0.017--0.635, *p* = 0.006), Fbg (OR = 2.550, 95% CI: 1.803--6.003, *p* = 0.032) and surgical type (OR = 3.612, 95% CI: 1.551--8.410, *p* = 0.003) were analyzed by a multivariate logistic regression model, indicating that they still showed significant correlations with symptomatic VTE ([Table VII](#t0007){ref-type="table"}). The risk of VTE in bilateral surgery was 3.612 times higher than that in the unilateral operation, and increasing Fbg would result in a 2.55-fold increase in the risk of VTE ([Table VII](#t0007){ref-type="table"}).

###### 

Univariate analysis of baseline characteristics between venous thromboembolism (VTE) and non-VTE patients

  Indicators                  TXA            Placebo                                                              
  --------------------------- -------------- -------------- ------- ------- -------------- -------------- ------- -------
  Number                      24             696                            39             1121                   
  Age, mean ± SD \[years\]:   66.74 ±7.694   66.46 ±8.937   0.146   0.884   68.71 ±9.151   68.37 ±8.454   0.229   0.821
   \< 60                      7              131            2.245   0.325   7              184            0.798   0.671
   60--79                     17             542                            27             836                    
   ≥ 80                       0              23                             5              101                    
  Gender, *n*:                                                                                                    
   Male                       9              166            2.305   0.129   10             174            2.892   0.140
   Female                     15             530                            29             947                    
  Mean BMI \[kg/m^2^\]:       26.75 ±3.80    26.08 ±4.08    0.793   0.428   27.19 ±3.62    26.23 ±3.97    1.489   0.137
   BMI \< 25                  4              249            2.926   0.044   9              422            2.830   0.046
   BMI ≥ 25                   20             447                            30             699                    
  Diagnosis, *n*:                                                                                                 
   OA                         22             636            0.132   0.717   36             1031           0.051   0.823
   Non-OA                     2              60                             3              90                     
  Smoking history, *n*:                                                                                           
   Yes                        3              85             0.075   0.783   6              134            0.769   0.380
   No                         21             611                            33             987                    
  Drinking history, *n*:                                                                                          
   Yes                        2              56             0.109   0.741   11             188            2.709   0.100
   No                         22             640                            28             933                    
  ASA rating, *n*:                                                                                                
   1--2                       22             645            0.025   0.876   34             999            0.014   0.904
   3                          2              51                             5              122                    

BMI -- body mass index, OA -- osteoarthritis, ASA -- American Society of Anesthesiologists, TXA -- tranexamic acid.

###### 

Univariate analysis of preoperative laboratory and medication between venous thromboembolism (VTE) and non-VTE patients

  Indicators                  TXA             Placebo                                                                 
  --------------------------- --------------- --------------- ------- ------- --------------- --------------- ------- -------
  Number                      24              696                             39              1121                    
  Pre-operative laboratory:                                                                                           
   PT \[s\]                   12.19 ±3.04     11.81 ±1.16     1.448   0.148   12.04 ±2.36     11.67 ±1.29     1.697   0.090
   INR                        1.09 ±0.27      1.04 ±0.42      0.841   0.409   1.14 ±0.33      1.09 ±0.25      1.213   0.225
   APTT \[s\]                 28.21 ±5.23     26.73 ±6.78     1.295   0.208   27.68 ±5.46     26.32 ±5.93     1.411   0.159
   Fbg                        2.73 ±0.70      3.05 ±0.70      0.196   0.046   2.83 ±0.67      3.09 ±0.81      1.981   0.048
   Hgb \[g/dl\]               133.13 ±13.60   130.89 ±14.33   0.776   0.445   130.47 ±13.87   129.76 ±13.46   0.324   0.746
   Hct (%)                    39.59 ±3.72     38.95 ±4.96     0.670   0.503   38.80 ±4.08     37.97 ±3.95     1.289   0.198
   Plt \[per mm^3^\]          209.96 ±61.31   217.84 ±60.67   0.625   0.532   205.73 ±64.59   212.64 ±66.67   0.637   0.524
  D-dimer, *n*:                                                                                                       
   Normal                     16              428             0.273   0.602   25              754             0.029   0.866
   Abnormal                   8               268                             14              376                     
  Premedication, *n*:                                                                                                 
   Aspirin                    2               20              0.855   0.355   4               43              2.516   0.113
   Lipid-lowering medicine    1               23              0.121   0.729   4               51              1.601   0.206

PT -- prothrombin time, INR -- international normalized ratio, APTT -- activated partial thromboplastin time, Fbg -- fibrinogen, Hgb -- hemoglobin, Hct -- hematocrit, Plt -- platelets, TXA -- tranexamic acid.

###### 

Univariate analysis of type and number of complications between venous thromboembolism (VTE) and non-VTE patients

  Indicators                                                    TXA   Placebo                                       
  ------------------------------------------------------------- ----- --------- ------- ------- ---- ------ ------- -------
  Number                                                        24    696                       39   1121           
  Type of complication[\*](#tf5-1){ref-type="table-fn"}, *n*:                                                       
   Hypertension                                                 13    383       0.018   0.894   16   544    0.576   0.448
   Diabetes                                                     4     123       0.022   0.882   6    201    0.038   0.845
   Cerebrovascular disease                                      5     66        2.216   0.137   5    188    0.187   0.665
   Arrhythmia                                                   1     23        0.119   0.729   1    42     0.002   0.963
   Hyperlipidemia                                               2     22        0.656   0.418   1    47     0.009   0.926
   History of malignancy                                        2     13        2.130   0.144   2    24     0.474   0.491
  Anemia \[g/l\]:                                                                                                   
   \< 120                                                       5     123       0.016   0.899   7    221    0.005   0.946
   ≥ 120                                                        19    573                       32   900            
  Number of complications, *n*:                                                                                     
   0--1                                                         13    485       1.781   0.182   22   729    0.879   0.349
   ≥ 2                                                          11    211                       17   392            

TXA -- tranexamic acid.

Not all cases were included.

###### 

Univariate analysis of surgery-related parameters between venous thromboembolism (VTE) and non-VTE patients

  Indicators         TXA   Placebo                                       
  ------------------ ----- --------- ------- ------- ---- ------ ------- -------
  Number             24    696                       39   1121           
  Anesthesia, *n*:                                                       
   GA                19    588       0.175   0.675   35   924    0.944   0.331
   Non-GA            5     108                       4    197            
  Surgery, *n*:                                                          
   Unilateral TKA    14    550       4.696   0.030   19   754    5.025   0.025
   Bilateral TKA     10    146                       20   367            
  Drainage, *n*:                                                         
   Yes               22    686       3.182   0.074   36   1088   1.468   0.226
   No                2     10                        3    33             
  Surgeon, *n*:                                                          
   A                 6     243       5.176   0.16    6    243    6.318   0.097
   B                 12    215                       12   215            
   C                 3     180                       3    180            
   D                 3     58                        3    58             

TKA -- total knee arthroplasty, GA -- general anesthesia, TXA -- tranexamic acid.

###### 

Multi-variate analysis of parameters between venous thromboembolism (VTE) and non-VTE patients

  Indicators   *B*      S.E.    Wald    d*f*   OR      95%CI   *P*-value   
  ------------ -------- ------- ------- ------ ------- ------- ----------- -------
  Surgery      1.284    0.431   8.864   1      3.612   1.551   8.41        0.003
  BMI          −1.548   0.558   7.686   1      0.213   0.071   0.635       0.006
  Fbg          0.936    0.437   4.59    1      2.55    1.803   6.003       0.032

BMI -- body mass index, Fbg -- fibrinogen, OR -- odds ratio, LL -- lower limit, UL -- upper limit.

Intervention and outcome of symptomatic venous thromboembolism patients {#sec3.3}
-----------------------------------------------------------------------

All symptomatic VTE patients recovered. After definite diagnosis, low-molecular-weight heparin was subcutaneously injected from once a day to 2 times a day. After taking warfarin anticoagulation, patients were discharged as outpatients. The INR of prothrombin time for outpatient follow-up monitoring was maintained as 2--3 for 3 months. Dosage injection changed with different symptoms. Six PE patients were found without lower-limb swelling, pain symptoms or difficulty to correct hypoxemia. Thus, the dosage of low-molecular-weight heparin was changed from prevention to treatment, and oral warfarin anticoagulation was stopped and the patients discharged 2 weeks later. The INR of prothrombin time in outpatient follow-up monitoring was maintained as 2--3 for 3 months. No death occurred within 90 days after the operation.

Discussion {#sec4}
==========

In order to decrease the risk of perioperative blood loss and transfusion, TXA has been extensively studied as an adjunct treatment for TKA \[[@cit0020]\]. However, TKA was one of the most highly risky procedures that would result in VTE \[[@cit0020], [@cit0023]\]. Hence, we sought to determine whether the usage of TXA was associated with increased risk of VTE.

There have been a variety of studies that reported the risk of VTE after TKA. Bin Abd Razak *et al.* \[[@cit0024]\] reported that in 531 Asian patients who underwent unilateral TKAs without drug anticoagulation after surgery, only 4 (0.75%) of them had symptomatic VTE, and 1 had symptomatic PE. However, in the meta-analysis by Januel *et al.*, 44,844 cases of THA or TKA were included in 47 randomized clinical controls and observational studies \[[@cit0025]\]. All the subjects received anticoagulation to prevent VTE, showing that the total incidences of symptomatic VTE, DVT and PE after TKA were 1.09%, 0.63% and 0.27%.

However, we found that conventional use of tranexamic acid sequential preventive anticoagulation after perioperative treatments made the incidence of symptomatic VTE 3.33%, which was slightly higher than in the literature. Many clinical studies and several meta-analyses have confirmed that this way could effectively reduce the rates of blood loss and transfusion in TKA without increasing the risk of complications \[[@cit0006]\]. The distinction might be explained by the different diagnostic methods used, such as lower limb venography and lower extremity deep vein ultrasound, as well as the inconsistent observation time. The time with VTE risk is much longer than hospital stay, in Bin Abd Razak's research \[[@cit0024]\]. The average hospital stay was 5.2 days, during which the specialist was consulted to determine whether VTE occurred. Follow-up observations were practiced by assessing the swelling of the body to determine VTE. In Januel's research, the average length of follow-up was only 13 days. In this study, the average hospital stay was 18.4 days, and the observation time was even longer \[[@cit0025]\]. Also, symptomatic VTE was evaluated and diagnosed as comprehensive (independent of health care based on scoring system). With the Wells score for symptoms, the detection rate of VTE might increase.

Poeran *et al.* \[[@cit0026]\] conducted a retrospective study of 870,000 patients with complete hip/knee replacement for 6 consecutive years in 510 hospitals in the United States, finding that the incidence of deep venous thrombosis after using TXA was 0.4%, while the incidence was 0.5% in the group not using TXA. In addition, the majority of publications showed that TXA has an acceptable safety profile without increased risk of VTE \[[@cit0012], [@cit0027]--[@cit0031]\]. Our study found that compared with the historical control group, the incidence of symptomatic venous thrombosis did not increase significantly after using TXA. We believe that after using TXA, TKA in the conventional prevention of anticoagulation did not increase the risk of postoperative symptomatic VTE. Meanwhile, conventional routine lower limb vein imaging was not necessary for screening DVT.

The increase of Fbg was an independent risk factor, since Fbg was mainly involved in the coagulation process, and it has been reported as an independent risk factor for coronary heart disease \[[@cit0006]\]. The increase of plasma Fbg synthesis would lead to increased plasma Fbg levels, enhanced coagulation and formation of thrombosis \[[@cit0032]\]. In accord with these studies, our research showed a similar result that increased Fbg was significantly related to VTE. On the other hand, we found that BMI lower than 25 kg/m^2^ was a protective factor for symptomatic VTE, and several reports have also confirmed this finding \[[@cit0033], [@cit0034]\]. Moreover, extension of surgery, especially extension due to the bilateral TKA when compared with unilateral, was an independent risk factor for postoperative TKA \[[@cit0035]\]. Thus, prediction of VTE risk and stratification of patients was an important step in the future. There are several main aspects necessary to reduce the risk of symptomatic VTE in the case of TXA.

Firstly, according to the preoperative conventional color Doppler ultrasound screening of deep vein thrombosis, TXA should not be used in the operation if the patient had a positive result. Secondly, with postoperative Wells score, timely screening of asymptomatic deep vein thrombosis, as well as timely treatment should be paid attention to. Lastly, physical prevention and early functional exercise were necessary.

This research had several limitations, mainly because the patients in our study and in historical research underwent different methods in using TXA, and were treated with different surgeons. Moreover, the final judgment of symptomatic VTE was based on the doctor's comprehensive consideration, and the judgments from different doctors would misguide the results. However, the VTE was judged according to the Wells score, so the study result was still reliable. Moreover, as the morbidity of symptomatic VTE was too low, its independent risk factor still needed a larger sample to analyze the result.

In conclusion, TXA appears to be a safe and efficacious medicine in TKA patients who are at high risk for VTE. Our study suggested that high BMI, low Fbg and bilateral simultaneous surgery might act as independent risk factors for VTE. For further safety evaluation, we need methods and procedures which are as uniform as possible in large-scale trials.
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